Kevin Kalinsky, MD, summarizes recent clinical data regarding the role of CDK 4/6 inhibitors
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, summarizes some recent clinical data regarding CDK 4/6 inhibitors and their expanding role in the management of early and late stage breast cancer
Kevin Kalinsky, MD, shares thoughts on the DESTINY-Breast01 clinical trial from SABCS 2020
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares thoughts on the DESTINY-Breast01 clinical trial investigating trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer who had received at least two lines of anti-HER2 based therapies
Kevin Kalinsky, MD, regarding CTCs as a predictor of overall survival in metastatic breast cancer
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, considers the role of circulating tumor cells (CTCs) as a predictor of overall survival in patients with metastatic breast cancer based on presentations from SABCS 2020
Kevin Kalinsky, MD, offers considerations when treating patients with HR+, HER2- breast cancer
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares what the hematologist/oncologist community should know regarding how we treat patients with HR+, HER2- breast cancer that has spread to 1-3 lymph nodes
Kevin Kalinsky, MD, considers the practice-changing potential of RxPONDER
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, offers opinion on whether results from the RxPONDER clinical trial presented at the 2020 San Antonio Breast Cancer Symposium are practice changing
Kevin Kalinsky, MD, shares impressions of the RxPONDER clinical trial presented at SABCS 2020
Dr. Kalinsky, Director, Glenn Family Breast Center, Winship Cancer Institute, Emory University, shares impressions of the RxPONDER clinical trial presented at the 2020 San Antonio Breast Cancer Symposium and considers whether genomic tumor tissue tests can determine the necessity of chemotherapy
Priya Rastogi, MD, on key takeaways for oncologists regarding the tolerability of CDK 4/6 inhibitors
Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, shares key takeaways for oncologists regarding the tolerability of CDK 4/6 inhibitors
Adam Brufsky, MD, PhD, elaborates on the clinical implications of DESTINY-Breast01 from SABCS 2020
Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, elaborates on the clinical implications of the DESTINY-Breast01 study investigating trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer
Priya Rastogi, MD, provides details on the subgroup of patients with Ki-67 status from monarchE
Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, shares thoughts on the subgroup of patients with Ki-67 status involved the monarchE clinical trial from SABCS 2020
Adam Brufsky, MD, PhD, discusses the issue of resistance to HER2-targeted therapy
Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, discusses the issue of resistance to HER2-targeted therapy
Adam Brufsky, MD, PhD, describes the treatment landscape of HER2+ metastatic breast cancer
Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, describes the treatment landscape of HER2+ metastatic breast cancer and speculates on emerging novel agents
Priya Rastogi, MD, elaborates on the role of abemaciclib in HR+, HER2- node positive breast cancer
Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, discusses the standard of care for patients with HR+, HER2- node positive high risk early breast cancer and the role of abemaciclib in this group of patients
Adam Brufsky, MD, PhD, considers the investigation of poziotinib in HER2+ metastatic breast cancer
Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, considers the ongoing investigation of poziotinib in patients with HER2+ metastatic breast cancer heavily pre-treated with HER2-targeted therapy
Priya Rastogi, MD, shares the design and outcomes of the monarchE clinical trial from SABCS 2020
Dr. Rastogi, Medical Oncologist, UPMC Hillman Cancer Center, Medical Director, National Surgical Adjuvant Breast and Bowel Project Foundation, shares the design and outcomes of the monarchE clinical trial investigating abemaciclib in combination with adjuvant endocrine therapy in patients with HR+, HER2− early breast cancer (EBC) presented at the 2020 San Antonio Breast Cancer Symposium
Adam Brufsky, MD, PhD, discusses results from the Phase III NALA study presented at SABCS 2020
Dr. Brufsky, Professor of Medicine and Co-Director of the Comprehensive Breast Cancer Center, University of Pittsburgh Hillman Cancer Center, discusses results from the new analysis of the Phase III NALA study investigating neratinib plus capecitabine versus lapatinib plus capecitabine in patients with third-line HER2+ metastatic breast cancer who entered the trial with central nervous system (CNS) metastases
Hope Rugo, MD, provides perspective on the clinical progress of CDK 4/6 inhibitors in breast cancer
Dr. Rugo, Director of Breast Oncology and Clinical Trials Education, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, provides perspective on the clinical progress of CDK 4/6 inhibitors in early breast cancer as presented at the 2020 San Antonio Breast Cancer Symposium
Hope Rugo, MD, examines data from the DESTINY-Breast01 clinical study presented at SABCS 2020
Dr. Rugo, Director of Breast Oncology and Clinical Trials Education, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, shares thoughts on the DESTINY-Breast01 clinical study investigating trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer who had received at least two lines of anti-HER2 based therapies
Hope Rugo, MD, offers key takeaways for physicians regarding KEYNOTE-355
Dr. Rugo, Director of Breast Oncology and Clinical Trials Education, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, offers key takeaways for physicians regarding KEYNOTE-355 investigating pembrolizumab in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple‑negative breast cancer whose tumors express PD-L1 (CPS ≥10) as presented at the 2020 San Antonio Breast Cancer Symposium
Hope Rugo, MD, considers chemotherapy recommendations based on findings from KEYNOTE-355
Dr. Rugo, Director of Breast Oncology and Clinical Trials Education, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, offers opinion on the type of chemotherapy recommended for patients with locally recurrent unresectable or metastatic triple‑negative breast cancer whose tumors express PD-L1 (CPS ≥10) based on findings from KEYNOTE-355
Hope Rugo, MD, shares the design and outcomes of KEYNOTE-355 presented at SABCS 2020
Dr. Rugo, Director of Breast Oncology and Clinical Trials Education, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, shares the design and outcomes of KEYNOTE-355 investigating pembrolizumab in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple‑negative breast cancer whose tumors express PD-L1 (CPS ≥10)
Hope Rugo, MD, considers the incidence of TNBC and what makes this disease so difficult to treat
Dr. Rugo, Director of Breast Oncology and Clinical Trials Education, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, considers the incidence of triple-negative breast cancer (TNBC) and what makes this disease so difficult to treat
Erika Hamilton, MD, considers the role of NGS testing for breast cancer patients
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, considers the role of next-generation sequencing (NGS) for breast cancer patients
Erika Hamilton, MD, regarding the use of CDK 4/6 inhibitors in clinical practice
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, regarding the use of CDK 4/6 inhibitors in clinical practice
Erika Hamilton, MD, on promising treatment options in the management of HER2+ advanced breast cancer
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, speculates on promising treatment options in the management of HER2+ advanced breast cancer
Erika Hamilton, MD, provides perspective on the latest immunotherapy treatment trends in TNBC
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, provides perspective on the latest immunotherapy treatment trends in triple-negative breast cancer (TNBC)
Erika Hamilton, MD, discusses findings from the MARIO-3 clinical trial presented at the 2020 SABCS
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses findings from the MARIO-3 Phase II study investigating a novel triplet in first-line triple negative breast cancer (TNBC) presented at the 2020 San Antonio Breast Cancer Symposium
Debra Patt, MD, PhD, MBA, speculates on exciting data in TNBC coming out of SABCS 2020
Dr. Patt, Executive Vice President, Texas Oncology, speculates on exciting data in triple-negative breast cancer (TNBC) coming out of the 2020 San Antonio Breast Cancer Symposium
Debra Patt, MD, PhD, MBA, summarizes data from the ExteNET trial presented at SABCS 2020
Dr. Patt, Executive Vice President, Texas Oncology, discusses the overall survival analysis from the ExteNET trial, investigating neratinib in HER2-positive patients presented at the 2020 San Antonio Breast Cancer Symposium
Debra Patt, MD, PhD, MBA, comments on findings from the KEYNOTE-355 trial
Dr. Patt, Executive Vice President, Texas Oncology, comments on findings from the KEYNOTE-355 trial presented at the 2020 San Antonio Breast Cancer Symposium
Debra Patt, MD, PhD, MBA, provides perspective on the latest immunotherapy treatment trends in TNBC
Dr. Patt, Executive Vice President, Texas Oncology, provides perspective on the latest immunotherapy treatment trends in triple-negative breast cancer (TNBC)
Debra Patt, MD, PhD, MBA, on the promising investigations of CDK4/6 inhibitors
Dr. Patt, Executive Vice President, Texas Oncology, offers opinion on promising research regarding the use of CDK4/6 inhibitors
Julie Gralow, MD, offers opinion on immunotherapy treatment trends in the management of TNBC
Dr. Gralow, Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Jill Bennett Endowed Professor of Breast Oncology, University of Washington, offers opinion on the latest immunotherapy treatment trends in the management of triple-negative breast cancer (TNBC)
Julie Gralow, MD, regarding the ITOMIC trial data from the 2020 San Antonio Breast Cancer Symposium
Dr. Gralow, Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Jill Bennett Endowed Professor of Breast Oncology, University of Washington, shares results from the ITOMIC trial presented at the 2020 San Antonio Breast Cancer Symposium
Julie Gralow, MD, elaborates on the issue of resistance to endocrine therapies
Dr. Gralow, Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Jill Bennett Endowed Professor of Breast Oncology, University of Washington, elaborates on the issue of resistance to endocrine therapies
Julie Gralow, MD, summarizes the RxPONDER trial from the 2020 San Antonio Breast Cancer Symposium
Dr. Gralow, Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Jill Bennett Endowed Professor of Breast Oncology, University of Washington, tells us about the RxPONDER trial presented at the 2020 San Antonio Breast Cancer Symposium
Julie Gralow, MD, provides details on the SWOG S0226 findings presented at SABCS 2020
Dr. Gralow, Director, Breast Medical Oncology, Seattle Cancer Care Alliance, Jill Bennett Endowed Professor of Breast Oncology, University of Washington, discusses results from SWOG S0226, investigating serum thymidine kinase 1 (TK1) in HR+ metastatic breast cancer
Elizabeth Mittendorf, MD, PhD, discusses the outcomes of the IMpassion-031 study
Dr. Mittendorf, Director of the Breast Immuno-Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Rob and Karen Hale Distinguished Chair, discusses the outcomes of the IMpassion-031 study investigating the neoadjuvant use of atezolizumab plus chemotherapy in early triple-negative breast cancer (TNBC)
Elizabeth Mittendorf, MD, PhD, on the implications of the IMpassion-130 and IMpassion-131 trials
Dr. Mittendorf, Director of the Breast Immuno-Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Rob and Karen Hale Distinguished Chair, on how we might reconcile the outcomes of the IMpassion-130 and IMpassion-131 clinical trials and what these trials mean for the treatment of metastatic triple-negative breast cancer (TNBC)
Elizabeth Mittendorf, MD, PhD, considers key takeaways from the Impassion-131 presented at ESMO 2020
Dr. Mittendorf, Director of the Breast Immuno-Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Rob and Karen Hale Distinguished Chair, considers key takeaways from the Impassion-131 clinical trial investigating first-line atezolizumab in combination with chemotherapy in metastatic triple-negative breast cancer (TNBC) presented at the 2020 ESMO Virtual Congress
Elizabeth Mittendorf, MD, PhD, discusses the IMpassion-130 clinical trial presented at ESMO 2020
Dr. Mittendorf, Director of the Breast Immuno-Oncology Program, Dana-Farber/Brigham and Women’s Cancer Center, Rob and Karen Hale Distinguished Chair, discusses the long-term overall survival analysis of the IMpassion-130 clinical trial investigating the atezolizumab and nab paclitaxel combination in triple negative metastatic breast cancer (TNBC) patients presented at the 2020 ESMO Virtual Congress
Aditya Bardia, MD, MPH, considers the practice-changing potential of the ASCENT study from ESMO 2020
Dr. Bardia, Assistant Professor of Medicine, Harvard Medical School, Attending Physician, Medical Oncology, Massachusetts General Hospital, speculates on whether the Phase III ASCENT study investigating sacituzumab govitecan in triple negative breast cancer (TNBC) is practice-changing in this hard to treat group of patients
Aditya Bardia, MD, MPH, describes the outcomes from the Phase III ASCENT study from ESMO 2020
Dr. Bardia, Assistant Professor of Medicine, Harvard Medical School, Attending Physician, Medical Oncology, Massachusetts General Hospital, describes the outcomes from the Phase III ASCENT study investigating sacituzumab govitecan in triple negative breast cancer (TNBC) patients
Aditya Bardia, MD, MPH, discusses the design of newly approved sacituzumab govitecan
Dr. Bardia, Assistant Professor of Medicine, Harvard Medical School, Attending Physician, Medical Oncology, Massachusetts General Hospital, discusses the design of newly approved sacituzumab govitecan and why this type of compound is effective in historically difficult to treat breast cancer
Erika Hamilton, MD, shares thoughts on tolerability in high risk early breast cancer patients
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, shares thoughts on the tolerability of abemaciclib added to hormonal therapy in high risk early breast cancer patients
Erika Hamilton, MD, considers the comparison between the monarchE and PALLAS clinical trials
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, considers the comparison between the monarchE and PALLAS clinical trials and why there is a difference in outcomes in the two adjuvant breast cancer studies
Erika Hamilton, MD, considers the significance of the MonarchE study & the use of abemaciclib
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, considers the impact of the monarchE study investigating the addition of abemaciclib to hormonal therapy in patients with high-risk HR+, HER2- early breast cancer as presented at ESMO20 and whether should abemaciclib should be widely adopted for use in this setting
Erika Hamilton, MD, regarding the Phase III monarchE trial presented at ESMO 2020
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the results of the Phase III monarchE trial investigating the addition of abemaciclib to hormonal therapy in patients with high-risk HR+, HER2- early breast cancer presented at the 2020 ESMO Virtual Congress
Erika Hamilton, MD, on how CDK4/6 inhibitors transformed the management of metastatic breast cancer
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, explains how CDK4/6 inhibitors have transformed the management of metastatic breast cancer
Erika Hamilton, MD, on the standard of care for high-risk early HR+, HER2- breast cancer
Dr. Hamilton, Medical Oncologist, Director of Breast and Gynecologic Research Program, Sarah Cannon Research Institute, considers the effectiveness of the current standard of care for the adjuvant treatment of patients with high-risk early HR+, HER2- breast cancer
Sara Hurvitz, MD, describes the recently reported results using PARP inhibition and cisplatin
Dr. Hurvitz, Associate Professor, David Geffen School of Medicine, describes the recently reported results using PARP inhibition with and without cisplatin to treat advanced breast cancer with HRD (homologous repair deficiencies)
Sara Hurvitz, MD, discusses the recently announced results of Monarch E and PALLAS adjuvant trials
Dr. Hurvitz, Associate Professor, David Geffen School of Medicine, discusses the recently announced results of both the Monarch E and PALLAS adjuvant trials in early stage high risk hormone receptor positive breast cancer
Sara Hurvitz, MD, shares design and outcomes of the HER2CLIMB study in advanced breast cancer
Dr. Hurvitz, Associate Professor, David Geffen School of Medicine, shares the design and outcomes of the HER2CLIMB study investigating tucatinib in advanced breast cancer
Debu Tripathy, MD, describes the evolving role of PARP inhibitors in breast cancer patients
Dr. Tripathy, Chair, Breast Medical Oncology, MD Anderson Cancer Center, describes the evolving role of PARP inhibitors in breast cancer patients exhibiting germline or somatic abnormalities in BRCA or HRD genes
Debu Tripathy, MD, introduces new information onCDK4/6 inhibitors discussed at ASCO20
Dr. Tripathy, Chair, Breast Medical Oncology, MD Anderson Cancer Center, introduces new information regarding CDK4/6 inhibitors for hormone receptor positive breast cancer discussed at ASCO20
Debu Tripathy, MD, on presentations pertaining to immunotherapy in early breast cancer treatment
Dr. Tripathy, Chair, Breast Medical Oncology, MD Anderson Cancer Center, reports on presentations presented at ASCO20 pertaining to immunotherapy in the treatment of early breast cancer
Debu Tripathy, MD, discusses recent FDA approvals and HER2+ metastatic breast cancer management
Dr. Tripathy, Chair, Breast Medical Oncology, MD Anderson Cancer Center, provides his perspective on tucatinib and the HER2CLIMB study presented at ASCO20 and trastuzumab deruxtecan (Enhertu) for HER2+ MBC patients
Nancy Lin, MD, on impressions of the Phase 2 study done the by the Translational Breast Cancer Consortium
Dr. Lin, Associate Chief, Susan F. Smith Center for Women's Cancers, discusses impressions of the Phase 2 study done by the Translational Breast Cancer Consortium investigating olaparib in metastatic breast cancer patients with the BRCA1 or BRCA2 mutation and presented at ASCO20
Nancy Lin, MD, explores the role of CDK4/6 inhibitors in metastatic breast cancer management
Dr. Lin, Associate Chief, Susan F. Smith Center for Women's Cancers, explores the role of CDK4/6 inhibitors today in the management of HR+, HER2- metastatic breast cancer and whether the PALLAS results impact the way metastatic patients are treated
Nancy Lin, MD, discusses the standard of care when adjuvant treating HR+, HER2- early breast cancer
Dr. Lin, Associate Chief, Susan F. Smith Center for Women's Cancers, discusses the standard of care for the adjuvant treatment of HR+, HER2- early breast cancer patients given the negative outcomes of the PALLAS study
Nancy Lin, MD, provides perspective on the global Phase 3 PALLAS trial regarding early breast cancer
Dr. Lin, Associate Chief, Susan F. Smith Center for Women's Cancers, provides perspective on the global Phase 3 PALLAS trial testing the addition of 2 years of palbociclib to standard adjuvant endocrine therapy in HR+, HER2- early breast cancer patients
Nancy Lin, MD, considers whether the results of the HER2CLIMB study will become a new care standard
Dr. Lin, Associate Chief, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, considers the results of the HER2CLIMB study and if tucatinib in combination with T and C should become a new standard of care for heavily treated metastatic breast cancer patients with brain metastases.
Nancy Lin, MD, on the design and outcomes of the HER2CLIMB study regarding metastatic breast cancer
Dr. Lin, Associate Chief, Susan F. Smith Center for Women's Cancers, shares the design and outcomes of the HER2CLIMB study investigating tucatinib in combination with T and C in patients with heavily treated metastatic breast cancer with brain metastases
Karen Lu, MD, illustrates challenges the MAGENTA study brings up associated with genetic counseling
Dr. Lu, Professor and Chair, MD Anderson Cancer Center, illustrates challenges the MAGENTA study brings up associated with genetic counseling
Karen Lu, MD, provides opinion on whether genetic counseling should be part of the SOP for breast and ovarian cancer risk
Dr. Lu, Professor and Chair, MD Anderson Cancer Center, provides opinion on whether genetic counseling should be part of the SOP when trying to identify people at risk for breast and ovarian cancer,
Karen Lu, MD, shares outcomes of the MAGENTA study investigating the role of genetic counseling
Dr. Lu, Professor and Chair, MD Anderson Cancer Center, shares outcomes of the MAGENTA study which investigates the role of genetic counseling as it relates to online testing for breast and ovarian cancer genetic risk
Véronique Diéras, MD, on the optimal setting in which to receive a PARP inhibitor
Dr. Diéras, Senior Medical Oncologist, Head, Breast Cancer Group, Department of Medical Oncology, Centre Eugène Marquis, Rennes, France, tells us about the setting in which a metastatic breast cancer patients should receive a PARP inhibitor
Véronique Diéras, MD, on BRCA-positive metastatic breast cancer & PARP inhibitors
Dr. Diéras, Senior Medical Oncologist, Head, Breast Cancer Group, Department of Medical Oncology, Centre Eugène Marquis, Rennes, France, on whether BRCA-positive metastatic breast cancer patients should receive a PARP inhibitor
George Sledge, MD, shares the most relevant findings from the MONARCH-2 trial
Dr. Sledge, Professor and Chief, Division of Oncology, Stanford Cancer Center, Stanford University School of Medicine, shares the most relevant findings from the MONARCH-2 trial investigating abemaciclib plus fulvestrant in women with metastatic hormone receptor-positive, HER2-negative breast cancer
Dennis J. Slamon, MD, PhD, on the significance of the phase III MONALEESA-3 trial
Dr. Slamon, Professor and Chief of Hematology/Oncology, UCLA Department of Medicine, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women's Cancer Research Program at Jonsson Comprehensive Cancer Center, on the significance of the phase III MONALEESA-3 trial compared to other regimens that have been studied in this population of breast cancer patients
Véronique Diéras, MD, elaborates on the BROCADE 3 study presented at ESMO 2019
Dr. Diéras, Senior Medical Oncologist, Head, Breast Cancer Group, Department of Medical Oncology, Centre Eugène Marquis, Rennes, France, discusses results from the phase III BROCADE 3 study investigating veliparib in breast cancer patients with BRCA mutations
Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment
Dr. Arun, Professor of Medicine, Breast Medical Oncology and Co-Director of Cancer Genetics, University of Texas, MD Anderson Cancer Center, tells us in which setting metastatic breast cancer patient should receive a PARP inhibitor
Banu Arun, MD, on PARP inhibitors in BRCA positive metastatic breast cancer
Dr. Arun, Professor of Medicine, Breast Medical Oncology and Co-Director of Cancer Genetics, University of Texas, MD Anderson Cancer Center, on whether BRCA positive metastatic breast cancer patients should receive a PARP inhibitor
Banu Arun, MD, regarding veliparib in breast cancer patients with BRCA mutations
Dr. Arun, Professor of Medicine, Breast Medical Oncology and Co-Director of Cancer Genetics, University of Texas, MD Anderson Cancer Center, shares results from the Phase III study investigating veliparib in breast cancer patients with BRCA mutations
Joyce O’Shaughnessy, MD, elaborates on the MONALEESA-3 trial presented at ESMO 2019
Dr. O’Shaughnessy, Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center, shares results from the MONALEESA-3 trial presented at the 2019 ESMO Congress
Joyce O’Shaughnessy, MD, shares relevant findings from the MONARCH-2 trial
Dr. O’Shaughnessy, Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center, shares relevant findings from the MONARCH-2 trial investigating abemaciclib plus fulvestrant in women with hormone receptor positive, HER2-negative metastatic breast cancer
Joyce O’Shaughnessy, MD, on the role of CDK4/6 inhibitors in the management of TNBC
Dr. O’Shaughnessy, Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center, considers the role of CDK4/6 inhibitors in the management of metastatic triple-negative breast cancer (TNBC)
Joyce O’Shaughnessy, MD, shares results of the Impassion130 trial presented at ESMO 2019
Dr. O’Shaughnessy, Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center, shares how triple negative metastatic breast cancer patients should be treated considering the results of the Impassion130 trial
Joyce O’Shaughnessy, MD, on differentiating CDK4/6 inhibitors
Dr. O’Shaughnessy, Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center, on differentiating CDK4/6 inhibitors in sub-groups of breast cancer patient
Sara M. Tolaney, MD, MPH, provides an overview of the results from the SOPHIA trial
Dr. Tolaney, Associate Director, Susan F. Smith Center for Women's Cancers, Director, Clinical Trials, Breast Oncology, Senior Physician, Assistant Professor of Medicine, Harvard Medical School, provides an overview of the results from the SOPHIA trial, a Phase III study of chemotherapy plus margetuximab or trastuzumab in HER+ metastatic breast cancer after pertuzumab and 1-3 lines of prior treatment
Debu Tripathy, MD, elaborates on the SOPHIA trial in HER+ metastatic breast cancer
Dr. Tripathy, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, tell us about the results of the SOPHIA trial, a Phase III study of chemotherapy plus margetuximab or trastuzumab in HER+ metastatic breast cancer after pertuzumab and 1-3 lines of prior treatment
Debu Tripathy, MD, regarding CDK 4/6 inhibitors in the treatment of breast cancer
Dr. Tripathy, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, tells us how CDK 4/6 inhibitors are being integrated into breast cancer treatment regimens
Debu Tripathy, MD, elaborates on outcomes from the ImPassion130 trial
Dr. Tripathy, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, tells us about the results of ImPassion130, the Phase III study adding atezolizumab to 1st line chemotherapy with nab-paclitaxel in patients with PD-L1 positive metastatic triple-negative breast cancer (TNBC)
Debu Tripathy, MD, shares the outcomes of the MONALEESA-7 in premenopausal metastatic breast cancer
Dr. Tripathy, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, shares the outcomes of the MONALEESA-7 trial in premenopausal metastatic breast cancer
Sara M. Tolaney, MD, MPH, on the efficacy & safety of combination eribulin + pembrolizumab
Dr. Tolaney, Associate Director, Susan F. Smith Center for Women's Cancers, Director, Clinical Trials, Breast Oncology, Senior Physician, Assistant Professor of Medicine, Harvard Medical School, discusses the efficacy and safety of combination eribulin and pembrolizumab in metastatic breast cancer
Debra Patt, MD, MPH, MBA, considers the role of CDK 4/6 inhibitors in advanced breast cancer
Dr. Patt, Executive Vice President, Policy, Academic Programs, Strategic Initiatives, Texas Oncology, considers the role of CDK 4/6 inhibitors in advanced breast cancer and whether these inhibitor are interchangeable in treatment planning
Sara M. Tolaney, MD, MPH, shares outcomes from the ImPassion130 study in TNBC
Dr. Tolaney, Associate Director, Susan F. Smith Center for Women's Cancers, Director, Clinical Trials, Breast Oncology, Senior Physician, Assistant Professor of Medicine, Harvard Medical School, tells us about the results of ImPassion130, the Phase III study adding atezolizumab to 1st line chemotherapy with nab-paclitaxel in patients with PD-L1 positive metastatic triple-negative breast cancer (TNBC)
Debra Patt, MD, MPH, MBA, regarding the implications of the ImPassion130 trial in TNBC
Dr. Patt, Executive Vice President, Policy, Academic Programs, Strategic Initiatives, Texas Oncology, tells us about the monumental results of the ImPassion130, a Phase III study adding atezolizumab to 1st line chemotherapy with nab-paclitaxel in patients with PD-L1 positive metastatic triple-negative breast cancer (TNBC)
Sara M. Tolaney, MD, MPH, shares outcomes from the MONALEESA-7 trial
Associate Director, Susan F. Smith Center for Women's Cancers, Director, Clinical Trials, Breast Oncology, Senior Physician, Assistant Professor of Medicine, Harvard Medical School, shares outcomes from the MONALEESA-7 trial in premenopausal metastatic breast cancer
Debra Patt, MD, MPH, MBA, on the important implications of the MONALEESA-7 trial
Dr. Patt, Executive Vice President, Policy, Academic Programs, Strategic Initiatives, Texas Oncology, shares outcomes from the MONALEESA-7 trial in premenopausal, metastatic breast cancer
Neelima Denduluri, MD, elaborates on the SOPHIA trial data in HER+ metastatic breast cancer
Dr. Denduluri, Associate Chair, US Oncology Research, Virginia Cancer Specialists, tell us about the results of the SOPHIA trial, a Phase III study of chemotherapy plus margetuximab or trastuzumab in HER+ metastatic breast cancer after pertuzumab and 1-3 lines of prior treatment
Neelima Denduluri, MD, regarding the EMBRACA trial in HER2- metastatic breast cancer
Dr. Denduluri, Associate Chair, US Oncology Research, Virginia Cancer Specialists, provides an overview of the results of the Phase III EMBRACA trial comparing efficacy & safety of talazoparib (TALA) to PCT (capecitabine, eribulin, gemcitabine, vinorelbine) in HER2- metastatic breast cancer
Neelima Denduluri, MD, discusses outcomes from the ImPassion130 trial
Dr. Denduluri, Associate Chair, US Oncology Research, Virginia Cancer Specialists, tells us about the results of ImPassion130, the Phase III study adding atezolizumab to 1st line chemotherapy with nab paclitaxel in patients with PD-L1-positive, metastatic, triple-negative breast cancer (TNBC)
Neelima Denduluri, MD, regarding the MONALEESA-7 trial in premenopausal metastatic breast cancer
Dr. Denduluri, Associate Chair, US Oncology Research, Virginia Cancer Specialists, elaborates on the outcomes from the MONALEESA-7 trial in premenopausal metastatic breast cancer
Howard A. "Skip" Burris III, MD, FACP, FASCO, comments on the TAILORx study from ASCO 2018
Dr. Burris considers the results from the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score breast cancer patients
Howard A. "Skip" Burris III, MD, FACP, FASCO, on the outcomes of the PERSEPHONE clinical trial
Dr. Burris considers the implications of the PERSEPHONE trial in early HER2+ breast cancer presented at the 2018 ASCO Annual Meeting
Neelima Denduluri, MD, on the outcomes of the SANDPIPER study presented at ASCO 2018
Dr. Denduluri elaborates on the results of the SANDPIPER study, specifically, whether adding taselisib to fulvestrant in ER+, PIK3CA-mutant breast cancer patients improved outcomes
Neelima Denduluri, MD, looks back on the Short-HER trial from the 2017 ASCO Annual Meeting
Dr. Denduluri puts the PERSEPHONE trial into context with the Short-HER trial from ASCO 2017 and considers the standard of care of 12 months of trastuzumab in the early breast cancer setting
Neelima Denduluri, MD, offers opinion on the PERSEPHONE trial in early HER2+ breast cancer
Dr. Denduluri considers whether the results of the PERSEPHONE trial in early HER2+ breast cancer mean that 6 months of trastuzumab can be given rather than 12 months in the adjuvant setting
Neelima Denduluri, MD, tells us about the recent updates to breast cancer guidelines
Dr. Denduluri shares changes that have been recently incorporated into breast cancer guidelines
Neelima Denduluri, MD, comments on the role of CDK4/6 inhibitors
Dr. Denduluri discusses how to differentiate CDK4/6 inhibitors and whether they be used interchangeably
Neelima Denduluri, MD, regarding the implications of the TAILORx study from ASCO 2018
Dr. Denduluri elaborates on the implications of the TAILORx study presented at the 2018 ASCO Annual Meeting
Neelima Denduluri, MD, speculates on the implications of taselisib data at ASCO 2018
Dr. Denduluri offers opinion on whether taselisib might one day become a standard of care based on the outcomes of the SANDPIPER study
Neelima Denduluri, MD, on the MONALEESA-3 study in HR+/HER2- advanced breast cancer
Dr. Denduluri elaborates on the significance of the improvement in the PFS fulvestrant +ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer
Neelima Denduluri, MD, considers whether the results of TAILORx are practice-changing
Dr. Denduluri offers opinion on the practice-changing results of the TAILORx study presented at the 2018 ASCO Annual Meeting
Julie Gralow, MD, speculates on taselisib as a standard of care based on the results of SANDPIPER
Dr. Gralow considers whether taselisib will become a standard of care one day because of the outcomes of the SANDPIPER study presented at the 2018 ASCO Annual Meeting
Julie Gralow, MD, tells us about the SANDPIPER proof of concept trial presented at ACSO 2018
Dr. Gralow considers the SANDPIPER study presented at the 2018 ASCO Annual Meeting and whether adding taselisib to fulvestrant in ER+, PIK3CA-mutant breast cancer patients improved outcomes
Julie Gralow, MD, comments on the practice-changing implications of the TAILORx study
Dr. Gralow shares her thoughts on the practice-changing TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients
Julie Gralow, MD, discusses outcomes from the TAILORx study presented at ASCO 2018
Dr. Gralow on whether the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients tells us endocrine therapy alone is similar in efficacy to chemoendocrine therapy
Julie Gralow, MD, regarding the reduction in cardiac events in the PERSEPHONE study
Dr. Gralow on whether the reduction of cardiac events in the PERSEPHONE study comparing 6 months versus 12 months of trastuzumab therapy in early breast cancer is compelling data
Julie Gralow, MD, reflects on the PERSEPHONE trial from the 2018 ASCO Annual Meeting
Dr. Gralow puts the PERSEPHONE trial into context with the ShortHER trial from the 2017 ASCO Annual Meeting as well as the standard of care of 12 months of trastuzumab in the early breast cancer setting
Julie Gralow, MD, on the implications of the PERSEPHONE trial in early HER2+ breast cancer
Dr. Gralow regarding the results of the PERSEPHONE trial in early HER2+ breast cancer presented at the 2018 ASCO Annual Meeting
Julie Gralow, MD, speaks to the significance of the MONALEESA-3 study
Dr. Gralow regarding the improvement in PFS fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer
Julie Gralow, MD, elaborates on how to differentiate CDK4/6 inhibitors
Dr. Gralow explains how to differentiate CDK4/6 inhibitors and whether they can be used interchangeably
Douglas W. Blayney, MD, discusses the biggest takeaway regarding breast cancer here at ASCO 2018
Dr. Blayney, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, discusses the biggest takeaway regarding breast cancer, in particular triple negative breast cancer, here at ASCO 2018
Douglas W. Blayney, MD, on if the results of the TAILORx study practice changing
Dr. Blayney, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, on if the results of the TAILORx study are practice changing
Douglas W. Blayney, MD, discusses the implications of the TAILORx study
Dr. Blayney, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, discusses the TAILORx study and if endocrine therapy alone is similar in efficacy to chemotherapy + endocrine therapy
Douglas W. Blayney, MD, discusses the MONALEESA-3 study in HR+/HER2- advanced breast cancer
Dr. Blayney, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, on the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer
Douglas W. Blayney, MD, on differentiating CDK4/6 Inhibitors and if they can be used interchangeably
Dr. Blayney, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, on differentiating CDK4/6 Inhibitors and if they can be used interchangeably
Sara M. Tolaney, MD, MPH on whether CDK4/6 inhibitors can be used interchangeably
Dr. Tolaney explains how to differentiate CDK4/6 inhibitors and considers whether they can be used interchangeably
Sara M. Tolaney, MD, MPH tells us about the outcomes of the MONARCH 2 study
Dr. Tolaney shares details from the MONARCH 2 study in pre and peri-menopausal ER+, HER2- breast cancer patients
Sara M. Tolaney, MD, MPH discusses the practice changing outcomes of the TAILORx study
Dr. Tolaney on if the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients, means endocrine therapy alone is similar in efficacy to chemotherapy + endocrine therapy
Sara M. Tolaney, MD, MPH, discusses the fulvestrant + ribociclib arm of the MONALEESA-3 study
Dr. Tolaney on how significant the improvement in PFS fulvestrant + ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer
Sara M. Tolaney, MD, MPH, on whether the results of the TAILORx study are “practice changing”
Dr. Tolaney on whether the results of the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients are “practice changing”
Debu Tripathy, MD, on immunotherapies being studied for treatment of metastatic breast cancer
Dr. Tripathy, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, reflects on how immunotherapies are being studied and possibly integrated into the treatment of metastatic breast cancer
Debu Tripathy, MD, shares his impressions of the MONALEESA-2 study
Dr. Tripathy, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, offers his take on the secondary analysis of the MONALEESA-2 study
Debu Tripathy, MD, regarding the results of the MONARCH-2 study
Dr. Tripathy, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, elaborates on how the results of the MONARCH-2 study presented at ASCO 2017 will impact the way he treats breast cancer patients
Debu Tripathy, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer
Dr. Tripathy, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the impact of the APHINITY study on treatment of adjuvant breast cancer
Mohammad Jahanzeb, MD, FACP, on immunotherapy and treatment of metastatic breast cancer
Dr. Jahanzeb, Professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, describes how immunotherapies are being studied and possibly integrated into the treatment of metastatic breast cancer
Mohammad Jahanzeb, MD, FACP, discusses the results of the MONARCH-2 study presented at ASCO
Dr. Jahanzeb, Professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, speculates on how the results of the MONARCH-2 study presented at ASCO 2017 could change the way we treat breast cancer patients
Mohammad Jahanzeb, MD, FACP, on the impact of the APHINITY study presented at ASCO
Dr. Jahanzeb, Professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, describes how the APHINITY study could impact the treatment of adjuvant breast cancer
Neelima Denduluri, MD, discusses exciting new approaches to treating breast cancer
Dr. Denduluri, Associate Chair, US Oncology Research Virginia Cancer Specialists, comments on the most exciting new approaches to treating breast cancer
Neelima Denduluri, MD, describes how CDK 4/6 inhibitors impact breast cancer treatment
Dr. Denduluri, Associate Chair, US Oncology Research, Virginia Cancer Specialists, elaborates on how CDK 4/6 inhibitors are changing the way breast cancer is treated, and how to differentiate between the various inhibitors
Neelima Denduluri, MD, on how the APHINITY study could impact treatment of adjuvant breast cancer
Dr. Denduluri, Associate Chair, US Oncology Research Virginia Cancer Specialists, explains how the APHINITY study could impact the treatment of adjuvant breast cancer
Neelima Denduluri, MD, discusses the results of the MONARCH-2 study presented at ASCO
Dr. Denduluri, Associate Chair, US Oncology Research Virginia Cancer Specialists, discusses the results of the MONARCH-2 study presented here at ASCO
Julie Gralow, MD, shares perspective on the evolving development immunotherapies in breast cancer
Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, shares her perspective on the evolving development of immunotherapies in breast cancer
Lee Schwartzberg, MD, interprets the results of the PALOMA-2 study presented at ASCO 2016
Lee Schwartzberg, MD, Professor of Medicine, Chief, Division of Hematology Oncology, University of Tennessee Health Science Center, provides his perspective on the results of the PALOMA-2 study and what it means for breast cancer treatment strategies
Lee Schwartzberg, MD, on how liquid biopsies can be used for breast cancer treatment strategies
Lee Schwartzberg, MD, Professor of Medicine, Chief, Division of Hematology Oncology, University of Tennessee Health Science Center, provides insights into two liquid biopsy tests that can be helpful in determining breast cancer treatment strategies
Julie Gralow, MD, shares her thoughts on the topic of liquid biopsy in breast cancer.
Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, shares her perspective on the concept of liquid biopsy and its potential role in breast cancer
Julie Gralow, MD, shares her thoughts on new drugs in development for breast cancer.
Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, shares her thoughts on investigational drugs in development for breast cancer such as androgen receptor targeted therapies, immunotherapies, and checkpoint inhibitors
Julie Gralow, MD, on the KRISTINE study
Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, comment on the KRISTINE study of preoperative treatment of HER2(+) breast cancer with T-DM1 plus pertuzumab versus the combination of docetaxol, carboplatin, trastuzumab, and pertuzumab
Julie Gralow, MD, discusses the Monarch 1 study
Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, comments on the Monarch 1 study of the investigational CDK4/6 inhibitor abemaciclib as a single agent in previously treated metastatic breast cancer as presented at ASCO 2016
Julie Gralow, MD, discusses the outcomes of the PALOMA-2 study presented at ASCO 2016
Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, discusses the outcomes of the PALOMA-2 trial which studied letrozole with or without the addition of CDK4/6 dual inhibitor palbociclib as presented at ASCO 2016
Jasgit Sachdev, MD, on new drugs for treating patients w/ triple negative breast cancer.
Jasgit Sachdev, MD, Director, Breast & GYN Early Trials Program, HonorHealth Research Institute, shares her thoughts on new drugs in development that may hold promise for treating patients with triple negative breast cancer
Jasgit Sachdev, MD, on liquid biopsy as a promising technology for breast cancer treatment
Jasgit Sachdev, MD, Director, Breast & GYN Early Trials Program, HonorHealth Research Institute, shares her thoughts on liquid biopsy as a promising technology to be further developed as a tool in the planning of breast cancer treatment
Jasgit Sachdev, MD, discusses the PALOMA-2 randomized study
Jasgit Sachdev, MD, Director, Breast & GYN Early Trials Program, HonorHealth Research Institute, shares her thoughts on the PALOMA-2 randomized study in the first-line treatment setting in metastatic breast cancer as presented at ASCO 2016
Mohammad Jahanzeb, MD, FACP on the role of CDK inhibitors and their evolving role in breast cancer
Mohammad Jahanzeb, MD, FACP, Professor of Clinical Medicine, Hematology/Oncology; Medical Director, Sylvester Comprehensive Cancer Center, discusses the role of CDK inhibitors and their evolving role in metastatic breast cancer
Mohammad Jahanzeb, MD, FACP comments on rising drug costs relative to more effective therapies
Mohammad Jahanzeb, MD, FACP, Professor of Clinical Medicine, Hematology/Oncology; Medical Director, Sylvester Comprehensive Cancer Center, shares his thoughts on the topic of rising drug costs relative to more effective therapies and their use over longer periods of time
Mohammad Jahanzeb, MD, FACP talks about impact of CDK4/6 inhibition added to letrozole
Mohammad Jahanzeb, MD, FACP, Professor of Clinical Medicine, Hematology/Oncology; Medical Director, Sylvester Comprehensive Cancer Center, comments on the results of the Paloma-2 trial which tested the impact of adding CDK4/6 inhibition to letrozole in metastatic hormone receptor positive breast cancer
Debu Tripathy, MD on the evidence of palbociclib (Ibrance) efficacy in the PALOMA-2 trial
Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center on reaffirmation of efficacy for Ibrance in the PALOMA-2 trial
Debu Tripathy, MD discusses the PALOMA-2 trial outcomes in ER+/HER2- advanced breast cancer
Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center weighs in on the PALOMA-2 trial efficacy outcomes
Debu Tripathy, MD, on the use of hormonal therapy in the PALOMA-2 clinical study
Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center describes how hormonal therapies were used in the PALOMA-2 study in particular in those with prior adjuvant therapy
Debu Tripathy, MD provides update on breast cancer treatment algorithms impacted by PD-L1
Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center talks on how PD-L1 impacts treatment algorithms in breast cancer
Debu Tripathy, MD explains how liquid biopsy figures into breast cancer treatment
Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center relays how liquid biopsy figures into the treatment of breast cancer
Debu Tripathy, MD regarding the MONARCH 1 (abemaciclib) study
Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center provides an update on the MONARCH 1 (abemaciclib) study at ASCO 2016
Debu Tripathy, MD on the importance of cdk4/6 for future breast cancer treatments
Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center weighs in on how important a role cdk4/6 inhibitors will play in future breast cancer treatments
Lee S. Schwartzberg, MD, FACP on exciting studies for breast cancer investigational agents
Lee S. Schwartzberg, MD, FACP, Professor of Medicine, Division of Hematology/Oncology, University of Tennessee Health Science Center relays the pipeline’s exciting investigational agents being studied in breast cancer
Lee S. Schwartzberg, MD, FACP discussing Paloma 2 study results from ASCO 2016
Lee S. Schwartzberg, MD, FACP, Professor of Medicine, Division of Hematology/Oncology, University of Tennessee Health Science Center on the results of the Paloma 2 study presented here at ASCO 2016
Debu Tripathy, MD, provides perspective on the treatment of HER2+ breast cancer patients
Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, provides the big picture on how treatment of HER2+ breast cancer patients is changing
Follow @OBRTweets